美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Marizyme, Inc.

0.0000

0.0000

成交量：- -

成交额：- -

市值：131.79

市盈率：0.00

高：0.0000

开：0.0000

低：0.0000

收：0.0000

52周最高：0.0081

52周最低：0.0000

股本：1.32亿

流通股本：6,100.70万

量比：- -

换手率：- -

股息：- -

股息率：- -

每股收益(TTM):-0.1349

每股收益(LYR):-1.4370

净资产收益率：-3137.71%

总资产收益率：-26.57%

市净率：-0.00

市盈率(LYR):NaN

数据加载中...

总览公司新闻资讯公告

公司资料

公司名字：

Marizyme, Inc.

交易所：

EXPERT

成立时间：

2007

员工人数：

13

公司地址：

555 Heritage Drive,Suite 205,Jupiter,Florida,United States

官网：

http://www.marizyme.com

邮编：

33458

电话：

传真：

- -

简介：

Marizyme, Inc.于2007年3月20日在内华达州注册成立。该公司是一家多技术生命科学公司，致力于加速、开发和商业化促进患者健康并呈现快速收入增长潜力的医疗技术。该公司专注于开发三个医疗技术平台——DuraGraft、MATLOC和Krillase——每个平台都经过临床测试，并由专利或正在申请专利的资产组合提供支持。DuraGraft是一种一次性的术中血管移植治疗，能够保护内皮细胞免受缺血性损伤和再灌注损伤，并减少CABG后与VGF相关的并发症，从而减少重复血运重建和心肌梗死等主要心脏不良事件，减少移植失败的发生率和并发症，并改善临床结果。MATLOC是用于CKD评估的床旁、片上实验室数字筛查和诊断设备平台。该公司的Krillase蛋白酶为伤口愈合、血栓形成和宠物健康提供治疗。

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/MRZM/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MRZM","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MRZM\",,,,,undefined,":{"symbol":"MRZM","market":"US","secType":"STK","nameCN":"Marizyme, Inc.","latestPrice":0.000001,"timestamp":1774468800000,"preClose":0.000001,"halted":0,"volume":0,"delay":15,"changeRate":0,"floatShares":61006967,"shares":131793088,"eps":-0.134879,"marketStatus":"盘后交易","change":0,"latestTime":"03-25 16:00:00 EDT 延时","open":0.000001,"high":0.000001,"low":0.000001,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.134879,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1774483200000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"EXPERT","adjPreClose":0.000001,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MRZM\",,,,,undefined,":{"symbol":"MRZM","floatShares":61006967,"roa":"-26.57%","roe":"-3137.71%","lyrEps":-1.437042,"shares":131793088,"dividePrice":0,"high":0.000001,"amplitude":0,"preClose":0.000001,"low":0.000001,"week52Low":0.000001,"pbRate":"-0.00","psRate":"0.00","week52High":0.0081,"institutionHeld":0,"latestPrice":0.000001,"eps":-0.134879,"divideRate":0,"volume":0,"delay":15,"ttmEps":-0.134879,"open":0.000001,"prevYearClose":0.000001,"prevWeekClose":0,"prevMonthClose":0,"prevQuarterClose":0,"fiveDayClose":0,"twentyDayClose":0,"sixtyDayClose":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MRZM\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-08-14","symbol":"MRZM","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盘后","type":"earning","dateTimestamp":1723608000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-05-28","symbol":"MRZM","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盘后","type":"earning","dateTimestamp":1716868800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-05-13","symbol":"MRZM","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盘后","type":"earning","dateTimestamp":1715572800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2023-11-14","symbol":"MRZM","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盘后","type":"earning","dateTimestamp":1699938000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2023-08-18","symbol":"MRZM","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盘后","type":"earning","dateTimestamp":1692331200000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MRZM\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MRZM\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":38038239,"yearFounded":2007,"employeeNum":13,"address":"555 Heritage Drive,Suite 205,Jupiter,Florida,United States","zipCode":"33458","officePhone":"561 935 9955"},"stockCompanyDetail":{"websiteUrl":"http://www.marizyme.com","description":"Marizyme, Inc.于2007年3月20日在内华达州注册成立。该公司是一家多技术生命科学公司，致力于加速、开发和商业化促进患者健康并呈现快速收入增长潜力的医疗技术。该公司专注于开发三个医疗技术平台——DuraGraft、MATLOC和Krillase——每个平台都经过临床测试，并由专利或正在申请专利的资产组合提供支持。DuraGraft是一种一次性的术中血管移植治疗，能够保护内皮细胞免受缺血性损伤和再灌注损伤，并减少CABG后与VGF相关的并发症，从而减少重复血运重建和心肌梗死等主要心脏不良事件，减少移植失败的发生率和并发症，并改善临床结果。MATLOC是用于CKD评估的床旁、片上实验室数字筛查和诊断设备平台。该公司的Krillase蛋白酶为伤口愈合、血栓形成和宠物健康提供治疗。","exchange":"EXPERT","name":"Marizyme, Inc.","nameEN":"Marizyme, Inc."}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"MRZM\",market:\"US\",,,undefined,":null}}